Cyclo Therapeutics, Inc.
CYTH · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 89.9% | -39.2% | -35% | – |
| Gross Profit | $0 | -$0 | -$0 | -$0 |
| % Margin | 92.8% | -656.4% | -313.2% | -181.5% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -3,545% | -4,576.2% | -2,522.6% | -1,810.4% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -3,778.4% | -4,858.7% | -2,145.3% | -1,812% |
| EPS Diluted | -0.31 | -0.21 | -0.15 | -0.23 |
| % Growth | -47.6% | -40% | 34.8% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | $0 | $0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |